Taysha Gene Therapies TSHA
$3.72 −$0.05 (-1.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.71 -0.27%
Open$3.67
Prev close$3.77
Day range$3.60 – $3.80
Volume3.15M
Market cap$1.21B
P/E (TTM)–
Dividend yield–
TSHA Stock News
Headlines matching Taysha Gene Therapies or the TSHA ticker, most recent first.
- Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating
- BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
- CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
- Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
- Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19
- Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
- Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13
- Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13 Positive
- BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14
- A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15
- Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $12 Positive
- Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)
- Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15 Positive
- BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $14 Positive
- BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 Positive
No comments yet — be the first to weigh in on TSHA.
Sign in to join the discussion.